Masahito Yasuda
- Dermatology top 5%
- Rheumatology top 10%
-
- Tumors and Oncological Cases 5
-
- Vascular Tumors and Angiosarcomas 7
- CAR-T cell therapy research 5
- Cutaneous Melanoma Detection and Management 4
-
- Nonmelanoma Skin Cancer Studies 5
-
- Skin and Cellular Biology Research 4
-
- Histiocytic Disorders and Treatments 4
-
- Psoriasis: Treatment and Pathogenesis 4
- Co-authors
- Osamu IshikawaAkira ShimizuTakayuki AsaoKyoichi KairaSei‐ichiro MotegiKenzo TakahashiAkiko SekiguchiHiroo Amano
- Journals
- Journal of Clinical Oncology (2 papers)SHILAP Revista de lepidopterología (2 papers)Scientific Reports (1 paper)
- Partner nations
- JapanUnited StatesMalaysia
In The Last Decade
Masahito Yasuda
47 papers receiving 530 citations
Peers
Comparison fields: 5 of 76
- Dermatology 128
- Rheumatology 99
- Pathology and Forensic Medicine 95
- Oncology 134
- Biochemistry 33
Countries citing papers authored by Masahito Yasuda
This map shows the geographic impact of Masahito Yasuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masahito Yasuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masahito Yasuda more than expected).
Fields of papers citing papers by Masahito Yasuda
This network shows the impact of papers produced by Masahito Yasuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masahito Yasuda. The network helps show where Masahito Yasuda may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Masahito Yasuda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2023 | 2 | |
| 3 | 2022 | 1 | |
| 4 | 2022 | 0 | |
| 5 | 2021 | 33 | |
| 6 | 2020 | 30 | |
| 7 | 2020 | 2 | |
| 8 | 2019 | 5 | |
| 9 | 2019 | 3 | |
| 10 | 2018 | 3 | |
| 11 | 2018 | 4 | |
| 12 | 2018 | 1 | |
| 13 | 2018 | 7 | |
| 14 | 2018 | 9 | |
| 15 | 2018 | 5 | |
| 16 | 2017 | 23 | |
| 17 | 2015 | 11 | |
| 18 | 2015 | 56 | |
| 19 | 2010 | 3 | |
| 20 | 2006 | 7 |
About Masahito Yasuda
Masahito Yasuda is a scholar working on Dermatology, Pathology and Forensic Medicine and Rheumatology, having authored 50 papers that have together received 536 indexed citations. Recurring topics across this work include Vascular Tumors and Angiosarcomas (7 papers), CAR-T cell therapy research (5 papers), Nonmelanoma Skin Cancer Studies (5 papers), Tumors and Oncological Cases (5 papers), Skin and Cellular Biology Research (4 papers), Histiocytic Disorders and Treatments (4 papers), Psoriasis: Treatment and Pathogenesis (4 papers) and Cutaneous Melanoma Detection and Management (4 papers). The work is most often cited by research in Dermatology (128 citations), Rheumatology (99 citations) and Pathology and Forensic Medicine (95 citations). Masahito Yasuda has collaborated with scholars based in Japan, United States and Malaysia. Frequent co-authors include Osamu Ishikawa, Akira Shimizu, Takayuki Asao, Kyoichi Kaira, Sei‐ichiro Motegi, Kenzo Takahashi, Akiko Sekiguchi, Hiroo Amano, Ayumi Takahashi and Yukie Endo. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.